Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: IMARC | PRODUCT CODE: 1518744

Cover Image

PUBLISHER: IMARC | PRODUCT CODE: 1518744

Germany Diabetes Market Report: 2024-2032

PUBLISHED:
PAGES: 134 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3699
PDF & Excel (5 User License)
USD 4699
PDF & Excel (Corporate License)
USD 5699

Add to Cart

The Germany diabetes market size reached US$ 11.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.8 Billion by 2032, exhibiting a growth rate (CAGR) of 2.9% during 2024-2032.

According to the International Diabetes Federation, diabetes is one of the most prevalent chronic diseases in Germany, with 9.5 million recorded incidences in 2019. Diabetes is a set of diseases caused by issues with insulin - a hormone produced by the pancreas that regulates blood sugar. During these conditions, either the pancreas does not produce the required amount of insulin or the body is not able to effectively use the hormone. There are three major types of diabetes, which include type 1, type 2 and gestational diabetes. Amongst these, type 1 diabetes is an autoimmune condition, which occurs when the body starts attacking the pancreas with antibodies that disable the organ to make insulin. Whereas, type 2 diabetes is a milder form of type 1 diabetes, where the insulin created by the pancreas is either not enough for the body or the latter is resistant to it. Gestational diabetes generally develops during the second or third trimester of pregnancy and disappears after delivery.

Despite several improvements and advancements in its detection and treatment processes, diabetes remains one of the primary reasons for severe complications in most patients in Germany, which include heart attacks, strokes, end-stage renal disease, blindness, and amputations of lower extremities. With the rising incidences of these problems, various digital care solutions have been introduced in the country to help people with diabetes. For instance, there has been a rise in the usage of real-life and -time behavioral and metabolic data for informing patients about the current insulin levels and helping them make treatment decisions. Other than this, the German federal disease control and prevention research institute, Robert Koch Institute (RKI), has been developing a public health surveillance system. It focuses on the collection of comparable, long-term data, and ensuring the establishment of efficient surveillance structures for monitoring relevant indicators of diabetes.

Moreover, several initiatives are being undertaken in the country to spread awareness about the rising prevalence of diabetes, which mostly occurs in children and adolescents. In June 2019, the 2nd World Conference on Diabetes and Endocrinology was organized in Berlin, which included various research presentations provided by global leaders in diabetes and endocrinology. Besides this, in 2019, a country-wide campaign, called 'Sche1sstyp', was initiated by the Germany-based research center, Helmholtz Zentrum Munchen. The campaign addresses the prevention and early detection of type 1 diabetes.

What we have achieved in this report:

Comprehensive situation analysis of the Germany diabetes epidemiology and its dynamics:

Focus of the Analysis:

Historical, current and future prevalence of diabetes in Germany

Historical, current and future prevalence of type-1 and type-2 diabetes in Germany

Historical, current and future prevalence of diabetes in the urban and rural regions in Germany

Historical, current and future prevalence of diabetes among males and females in Germany

Historical, current and future prevalence of diabetes among various age groups in Germany

Historical, current and future diagnosis rates for diabetes in Germany

Historical, current and future drug treatment rates for diabetes in Germany

Comprehensive situation analysis of the Germany Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

Performance of the Oral Antidiabetics market in Germany

Performance of key classes

Performance of key players

Market outlook

Comprehensive situation analysis of the Germany Insulin market and its dynamics:

Focus of the Analysis:

Performance of the Insulin market in Germany

Performance of key classes

Performance of key players

Market outlook

Product Code: SR112024A687

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Diabetes Disease Overview

  • 5.1 What is Diabetes?
  • 5.2 Diabetes Diagnosis and Treatment
    • 5.2.1 Diagnosis
    • 5.2.2 Treatment
  • 5.3 Diabetes Complications

6 Germany Diabetes Epidemiology

  • 6.1 Diabetes Population and Prevalence Rates
  • 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
  • 6.3 Population and Prevalence Rates by Region
  • 6.4 Population and Prevalence Rates by Gender
  • 6.5 Population and Prevalence Rates by Age Group

7 Germany Diabetes Market

  • 7.1 Market Overview
  • 7.2 Market Performance
  • 7.3 Impact of COVID-19
  • 7.4 Market Forecast
  • 7.5 SWOT Analysis
    • 7.5.1 Overview
    • 7.5.2 Strengths
    • 7.5.3 Weaknesses
    • 7.5.4 Opportunities
    • 7.5.5 Threats
  • 7.6 Value Chain Analysis
  • 7.7 Porter's Five Forces Analysis
    • 7.7.1 Overview
    • 7.7.2 Bargaining Power of Buyers
    • 7.7.3 Bargaining Power of Suppliers
    • 7.7.4 Degree of Competition
    • 7.7.5 Threat of New Entrants
    • 7.7.6 Threat of Substitutes
  • 7.8 Market Breakup by Segment
    • 7.8.1 Germany Oral Antidiabetics Market
      • 7.8.1.1 Historical Market Trends
      • 7.8.1.2 Market Breakup by Class
      • 7.8.1.3 Market Shares of Key Players
      • 7.8.1.4 Market Forecast
    • 7.8.2 Germany Insulin Market
      • 7.8.2.1 Historical Market Trends
      • 7.8.2.2 Market Breakup by Class
      • 7.8.2.3 Market Shares of Key Players
      • 7.8.2.4 Market Forecast

8 Competitive Landscape

  • 8.1 Competitive Structure
  • 8.2 Profiles of Key Players
Product Code: SR112024A687

List of Figures

  • Figure 1: The Impact of Diabetes in the Human Body
  • Figure 2: Diabetes Complications
  • Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2023 & 2032
  • Figure 4: Body Mass Index and Relative risk of Type-2 Diabetes
  • Figure 5: Germany: Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 6: Germany: Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 7: Germany (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 8: Germany (Type1 & Type2): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 9: Germany (Urban & Rural): Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 10: Germany (Urban & Rural): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 11: Germany (Male & Female): Total Number of Diabetes Patients (in 000), 2018-2023
  • Figure 12: Germany (Male & Female): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
  • Figure 13: Germany: Total Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79, in 000), 2018-2023
  • Figure 14: Germany: Total Number of Diabetes Forecast Patients by Age Group (20-39, 40-59, 60-79, in 000), 2024-2032
  • Figure 15: Germany: Diabetes Drug Industry Overview
  • Figure 16: Germany: Diabetes Drug Market: Sales Value (in Billion US$), 2018-2023
  • Figure 17: Germany: Diabetes Drug Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 18: Germany: Diabetes Drug Market: SWOT Analysis
  • Figure 19: Germany: Diabetes Drug Market: Value Chain Analysis
  • Figure 20: Germany: Diabetes Drug Market: Porters Five Forces Analysis
  • Figure 21: Germany: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2018-2023
  • Figure 22: Germany: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2024-2032
  • Figure 23: Germany: Oral Antidiabetics Market: Sales Value (in Million US$), 2018-2023
  • Figure 24: Germany: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2018 & 2023
  • Figure 25: Germany: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
  • Figure 26: Germany: Oral Antidiabetics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Germany: Insulin Market: Sales Value (in Million US$), 2018-2023
  • Figure 28: Germany: Breakup of Insulin Market by Class (in %), 2018 & 2023
  • Figure 29: Germany: Insulin Market: Sales Share of Key Players (in %)
  • Figure 30: Germany: Insulin Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Diagnosis of Diabetes
  • Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2023 & 2032
  • Table 3: Germany: Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 4: Germany (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 5: Germany (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 6: Germany (Male & Female): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
  • Table 7: Germany: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79, in 000), 2018, 2023 & 2032
  • Table 8: Germany: Diabetes Drug Market: Competitive Structure
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!